800 Chesapeake Dr
Redwood City, CA 94063-4748
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Our approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Our product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. We believe our product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer. We utilize our proprietary technologies to (1) identify, isolate and evaluate CSCs, (2) identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation, and (3) develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. These targets are in pathways implicated in cancer biology and stem cell biology, including the Notch, Wnt and other fundamental CSC pathways. We believe our suite of proprietary CSC and antibody platform technologies provides a competitive advantage in cancer drug discovery. All of our product candidates were discovered internally in our own research laboratories. We have three anti-CSC product candidates in clinical development and we filed an Investigational New Drug, or IND, application in April 2012 for a fourth product candidate. We are also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has assembled a proven management team and is funded by top-tier investors. Since our founding in August 2004, we have raised approximately $300 million, consisting of approximately $187 million in the form of equity financings and approximately $112 million in the form of collaboration funding from our pharmaceutical partnerships. The company has advanced multiple internally discovered programs to clinical testing.
Clinical Development Stage
IND; Phase I; Phase II; PreClinical